摘要
200例骨量减少、年龄在45～80岁的绝经后妇女随机分为4组，进行不同干预方案治疗，治疗12个月后，双膦酸盐（固邦）组骨密度提高最明显（腰椎为3．5％，全髋为2．6％，均P〈0．05），选择性雌激素受体调节剂（贝邦）组（腰椎为2．0％，19〈0．05），骨转换指标均改善（均P〈0．05），活性维生素D（萌格旺）和钙剂（钙尔奇D）组骨密度和骨转换指标均无明显改变。
Two hundreds postmenopausal-women with osteopenia, aged 45-80, were randomly divided into 4 groups, and received different drug interventions. After treatment for 12 months, the lumbar spine bone mineral density （BMD） and total hip BMD in alendronate group increased significantly （ 3.5 % and 2. 6 %, both P〈0.05 ）, the lumbar spine BMD raised 2. 0% in selective estrogen receptor regulator group （P〈 0. 05 ）. Bone turnover indices improved in both groups（ all P〈0. 05 ）. No change in BMD or bone turnover indices was found in patients treated with active vitamin D3 and calcium.
出处
《中华内分泌代谢杂志》
CAS
CSCD
北大核心
2011年第6期502-504,共3页
Chinese Journal of Endocrinology and Metabolism
基金
上海市慢性病防治项目（SItDC12007311）
关键词
骨量减少
骨密度
骨质疏松
绝经后
Osteopenia
Bone mineral density
Osteoporosis, postmenopausal
